Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of giving ridaforolimus and
vorinostat together in treating patients with advanced solid tumors or lymphoma. Giving
ridaforolimus in combination with vorinostat may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth.